Early Intervention with High-Dose Steroid Pulse Therapy Prolongs Disease-Free Interval of Severe Alopecia Areata: A Retrospective Study

被引:18
|
作者
Yang, Chao-Chun [1 ,2 ]
Lee, Chun-Te [1 ]
Hsu, Chao-Kai [1 ,2 ]
Lee, Yi-Pei [1 ]
Wong, Tak-Wah [1 ]
Chao, Sheau-Chiou [1 ]
Lee, Julia Yu-Yun [1 ]
Sheu, Hamm-Ming [1 ]
Chen, WenChieh [3 ]
机构
[1] Natl Cheng Kung Univ, Coll Med, Dept Dermatol, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan
[3] Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany
关键词
Alopecia areata; Corticosteroids; Pulse drug therapy; Treatment; CORTICOSTEROID-THERAPY; GUIDELINES; MANAGEMENT;
D O I
10.5021/ad.2013.25.4.471
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Spontaneous recovery of severe alopecia areata is rare and the condition is difficult to treat. Objective: The aim of this study is to investigate and compare the effects and safety of steroid pulse therapy between oral and intravenous administrations between 1999 and 2010 at the Department of Dermatology, National Cheng Kung University Hospital. Methods: Data were retrospectively retrieved. A satisfactory response was defined as more than 75% hair regrowth in the balding area. Results: A total of 85 patients with more than 50% hair loss were identified and treated, with an overall satisfactory response rate of 51.8%. The mean follow-up time was 37.6 months, with a relapse rate of 22.7%. Patients with alopecia areata (hereafter, AA) of recent onset within one year showed higher response rates (p<0.001) and lower relapse rates compared to patients with AA persisting for more than 1 year. Further, even in patients with alopecia totalis, alopecia universal is or ophiasis type, early treatment resulted in a satisfactory response rate of 47% among the treated patients. In general, oral therapy was as effective and well-tolerated as intravenous therapy. Conclusion: The response rate is determined by disease severity and time of intervention, not by the administration form of steroid pulse therapy. Oral steroid pulse therapy can be considered as the first-line treatment for patients with severe AA of recent onset within one year.
引用
收藏
页码:471 / 474
页数:4
相关论文
共 50 条
  • [21] High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
    Cao, Wei
    Liu, Xiaosheng
    Hong, Ke
    Ma, Zhiyong
    Zhang, Yuelun
    Lin, Ling
    Han, Yang
    Xiong, Yong
    Liu, Zhengyin
    Ruan, Lianguo
    Li, Taisheng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [22] Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease
    Weissel, M
    Hauff, W
    THYROID, 2000, 10 (06) : 521 - 521
  • [23] A STUDY OF ADVERSE-EFFECTS OF HIGH-DOSE INTRAVENOUS (PULSE) METHYLPREDNISOLONE THERAPY IN PATIENTS WITH RHEUMATIC DISEASE
    BAETHGE, BA
    LIDSKY, MD
    GOLDBERG, JW
    ANNALS OF PHARMACOTHERAPY, 1992, 26 (03) : 316 - 320
  • [24] Comparison of tocilizumab and high-dose methylprednisolone pulse on outcomes in severe corona virus disease-2019: TAME-COVID, a retrospective multicentric study
    Kumar, Vipin
    Kashyap, Anil Kumar
    Kaur, Simran
    John, Mary
    Sibia, Raminderpal Singh
    Chopra, Vishal
    Singla, Tanvi
    Jindal, Jyoti
    Sethi, Suman
    Chhabra, Sandeep
    Berry, Amit
    Dhooria, Harmeet Singh
    Singh, Akashdeep
    Garg, Vikas
    Jain, Dinesh
    Mahajan, Rajesh
    Gautam, Parshotam Lal
    Midha, Vandana
    Mohan, Bishav
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2021, 11 (04) : 263 - 269
  • [25] PRIMARY OSTEOGENIC-SARCOMA OF THE SKULL - 5-YEAR DISEASE-FREE SURVIVAL FOLLOWING SURGERY AND HIGH-DOSE METHOTREXATE THERAPY
    SUNDARESAN, N
    GALICICH, JH
    ROSEN, G
    HUVOS, AG
    NEW YORK STATE JOURNAL OF MEDICINE, 1985, 85 (10) : 598 - 599
  • [26] Therapy with high-dose long-term antioxidant free radicals for severe paraquat poisoning: A pilot study
    Hu, Shunlin
    Qiao, Chuanhu
    Yuan, Zhengli
    Li, Min
    Ye, Jiangfeng
    Ma, Huimin
    Wang, Jinghui
    Xin, Siyi
    Zhang, Jing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (06) : 5149 - 5155
  • [27] High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China (vol 12, 627844, 2021)
    Cao, Wei
    Liu, Xiaosheng
    Hong, Ke
    Ma, Zhiyong
    Zhang, Yuelun
    Lin, Ling
    Han, Yang
    Xiong, Yong
    Liu, Zhengyin
    Ruan, Lianguo
    Li, Taisheng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [28] High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study
    Zeiner, Carsten
    Schroeder, Malte
    Metzner, Selina
    Herrmann, Johannes
    Notz, Quirin
    Hottenrott, Sebastian
    Roeder, Daniel
    Meybohm, Patrick
    Lepper, Philipp M.
    Lotz, Christopher
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [29] High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study
    Carsten Zeiner
    Malte Schröder
    Selina Metzner
    Johannes Herrmann
    Quirin Notz
    Sebastian Hottenrott
    Daniel Röder
    Patrick Meybohm
    Philipp M. Lepper
    Christopher Lotz
    BMC Pulmonary Medicine, 23
  • [30] Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study
    Manesh, Abi
    Gautam, Priyanka
    Kumar, D. Selwyn Selva
    Mannam, Pavithra
    Jasper, Anitha
    Gunasekaran, Karthik
    Thomas, Naveen Cherian
    Benjamin, Rohit Ninan
    Inbaraj, Leeberk Raja
    Devasagayam, Emily
    George, Mithun Mohan
    Karthik, Rajiv
    Abraham, Ooriapadickal Cherian
    Vanjare, Harshad A.
    Sivadasan, Ajith
    Appaswamy, Prabhakar Thirumal
    Jonathan, Edmond
    Michael, Joy S.
    Samuel, Prasanna
    Varghese, George M.
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) : 1460 - 1467